drugset / Trial / NCT07666490

BETRI-Prospective: Asthma Control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 μg]) vs Single Inhaler ICS/LABA (200/6 pMDI [BDP/FF - 200/6 μg])

NCT07666490

Phase 4 Not yet recruiting 644 enrolled Chiesi Farmaceutici S.p.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with a BDP/FF/GB 100/6/12.5 µg on asthma control outcomes relative to ICS/LABA therapy with BDP/FF 200/6 μg in a population with asthma poorly controlled.

Timeline

Start
2026-06-12
Primary completion
2028-06-13
Completion
2028-06-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glycopyrronium Unknown 12.5 ug Inhaled
Comparator beclomethasone dipropionate Other / unclassified 100 ug Inhaled
Comparator beclomethasone dipropionate Other / unclassified 200 ug Inhaled
Comparator Formoterol Other / unclassified 6 ug Inhaled

Indications